Search

Your search keyword '"Goni, Elisabetta"' showing total 168 results
Start Over Author "Goni, Elisabetta"
168 results on '"Goni, Elisabetta"'

2. A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich

Author

Zhang, Danmei, Dorman, Klara, Heinrich, Kathrin, Weiss, Lena, Boukovala, Myrto, Haas, Michael, Greif, Philipp A., Ziemann, Frank, Beyer, Georg, Roessler, Daniel, Goni, Elisabetta, Renz, Bernhard, D’Haese, Jan G., Kunz, Wolfgang G., Seidensticker, Max, Corradini, Stefanie, Niyazi, Maximilian, Ormanns, Steffen, Kumbrink, Jörg, Jung, Andreas, Mock, Andreas, Rudelius, Martina, Klauschen, Frederick, Werner, Jens, Mayerle, Julia, von Bergwelt-Baildon, Michael, Boeck, Stefan, Heinemann, Volker, and Westphalen, C. Benedikt

Published
2023
Full Text
View/download PDF

3. Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

Author

Drewes, A. Mohr, Haas, S.L., Hoyer, B.F., Hampe, J., Hinrichs, C. Noreen, Lerch, M.M., Aghdassi, A.A., Grote, T., Heuser, D.J., Ignatavicius, P., Malecka-Panas, E., Domínguez-Muñoz, J.E., López-Serrano, A., Auriemma, F., Oracz, G., Duman, D., Gubergrits, N., Overbeek, Kasper A., Poulsen, Jakob L., Lanzillotta, Marco, Vinge-Holmquist, Olof, Macinga, Peter, Demirci, A. Fatih, Sindhunata, Daniko P., Backhus, Johanna, Algül, Hana, Buijs, Jorie, Levy, Philippe, Kiriukova, Mariia, Goni, Elisabetta, Hollenbach, Marcus, Miksch, Rainer C., Kunovsky, Lumir, Vujasinovic, Miroslav, Nikolic, Sara, Dickerson, Luke, Hirth, Michael, Neurath, Markus F., Zumblick, Malte, Vila, Josephine, Jalal, Mustafa, Beyer, Georg, Frost, Fabian, Carrara, Silvia, Kala, Zdenek, Jabandziev, Petr, Sisman, Gurhan, Akyuz, Filiz, Capurso, Gabriele, Falconi, Massimo, Arlt, Alexander, Vleggaar, Frank P., Barresi, Luca, Greenhalf, Bill, Czakó, László, Hegyi, Peter, Hopper, Andrew, Nayar, Manu K., Gress, Thomas M., Vitali, Francesco, Schneider, Alexander, Halloran, Chris M., Trna, Jan, Okhlobystin, Alexey V., Dagna, Lorenzo, Cahen, Djuna L., Bordin, Dmitry, Rebours, Vinciane, Mayerle, Julia, Kahraman, Alisan, Rasch, Sebastian, Culver, Emma, Kleger, Alexander, Martínez-Moneo, Emma, Røkke, Ola, Hucl, Tomas, Olesen, Søren S., Bruno, Marco J., Della-Torre, Emanuel, Beuers, Ulrich, Löhr, J.-Matthias, and Rosendahl, Jonas

Published
2024
Full Text
View/download PDF

4. Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board

Author

Heinrich, Kathrin, Miller-Phillips, Lisa, Ziemann, Frank, Hasselmann, Korbinian, Rühlmann, Katharina, Flach, Madeleine, Biro, Dorottya, von Bergwelt-Baildon, Michael, Holch, Julian, Herold, Tobias, von Baumgarten, Louisa, Greif, Philipp A., Jeremias, Irmela, Wuerstlein, Rachel, Casuscelli, Jozefina, Spitzweg, Christine, Seidensticker, Max, Renz, Bernhard, Corradini, Stefanie, Baumeister, Philipp, Goni, Elisabetta, Tufman, Amanda, Jung, Andreas, Kumbrink, Jörg, Kirchner, Thomas, Klauschen, Frederick, Metzeler, Klaus H., Heinemann, Volker, and Westphalen, C. Benedikt

Published
2023
Full Text
View/download PDF

5. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board

Author

Dorman, Klara, Zhang, Danmei, Heinrich, Kathrin, Reeh, Laurens, Weiss, Lena, Haas, Michael, Beyer, Georg, Rössler, Daniel, Goni, Elisabetta, Renz, Bernhard W., D’Haese, Jan G., Kunz, Wolfgang G., Seidensticker, Max, Corradini, Stefanie, Niyazi, Maximilian, Ormanns, Steffen, Kumbrink, Jörg, Jung, Andreas, Klauschen, Frederick, Werner, Jens, Mayerle, Julia, von Bergwelt-Baildon, Michael, Boeck, Stefan, Heinemann, Volker, and Westphalen, C. Benedikt

Published
2023
Full Text
View/download PDF

6. HLA-DRB1∗16 and -DQB1∗05 alleles are strongly associated with autoimmune pancreatitis in a cohort of hundred patients

Author

Goni, Elisabetta, Regel, Ivonne, Mahajan, Ujjwal Mukund, Amodio, Antonio, De Marchi, Giulia, Beyer, Georg, Zuppardo, Raffaella Alessia, Di Leo, Milena, Lanzillotta, Marco, Bonatti, Francesco, Kauke, Teresa, Dick, Andrea, Weiss, Frank Ulrich, Schönermarck, Ulf, Lerch, Markus M., Frulloni, Luca, Cavestro, Giulia Martina, and Mayerle, Julia

Published
2022
Full Text
View/download PDF

8. Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

Author

Overbeek, Kasper A., primary, Poulsen, Jakob L., additional, Lanzillotta, Marco, additional, Vinge-Holmquist, Olof, additional, Macinga, Peter, additional, Demirci, A. Fatih, additional, Sindhunata, Daniko P., additional, Backhus, Johanna, additional, Algül, Hana, additional, Buijs, Jorie, additional, Levy, Philippe, additional, Kiriukova, Mariia, additional, Goni, Elisabetta, additional, Hollenbach, Marcus, additional, Miksch, Rainer C., additional, Kunovsky, Lumir, additional, Vujasinovic, Miroslav, additional, Nikolic, Sara, additional, Dickerson, Luke, additional, Hirth, Michael, additional, Neurath, Markus F., additional, Zumblick, Malte, additional, Vila, Josephine, additional, Jalal, Mustafa, additional, Beyer, Georg, additional, Frost, Fabian, additional, Carrara, Silvia, additional, Kala, Zdenek, additional, Jabandziev, Petr, additional, Sisman, Gurhan, additional, Akyuz, Filiz, additional, Capurso, Gabriele, additional, Falconi, Massimo, additional, Arlt, Alexander, additional, Vleggaar, Frank P., additional, Barresi, Luca, additional, Greenhalf, Bill, additional, Czakó, László, additional, Hegyi, Peter, additional, Hopper, Andrew, additional, Nayar, Manu K., additional, Gress, Thomas M., additional, Vitali, Francesco, additional, Schneider, Alexander, additional, Halloran, Chris M., additional, Trna, Jan, additional, Okhlobystin, Alexey V., additional, Dagna, Lorenzo, additional, Cahen, Djuna L., additional, Bordin, Dmitry, additional, Rebours, Vinciane, additional, Mayerle, Julia, additional, Kahraman, Alisan, additional, Rasch, Sebastian, additional, Culver, Emma, additional, Kleger, Alexander, additional, Martínez-Moneo, Emma, additional, Røkke, Ola, additional, Hucl, Tomas, additional, Olesen, Søren S., additional, Bruno, Marco J., additional, Della-Torre, Emanuel, additional, Beuers, Ulrich, additional, Löhr, J.-Matthias, additional, Rosendahl, Jonas, additional, Drewes, A. Mohr, additional, Haas, S.L., additional, Hoyer, B.F., additional, Hampe, J., additional, Hinrichs, C. Noreen, additional, Lerch, M.M., additional, Aghdassi, A.A., additional, Grote, T., additional, Heuser, D.J., additional, Ignatavicius, P., additional, Malecka-Panas, E., additional, Domínguez-Muñoz, J.E., additional, López-Serrano, A., additional, Auriemma, F., additional, Oracz, G., additional, Duman, D., additional, and Gubergrits, N., additional

Published
2024
Full Text
View/download PDF

9. Type 1 Autoimmune Pancreatitis in Europe:Clinical Profile and Response to Treatment

Author

Overbeek, Kasper A., Poulsen, Jakob L., Lanzillotta, Marco, Vinge-Holmquist, Olof, Macinga, Peter, Demirci, A. Fatih, Sindhunata, Daniko P., Backhus, Johanna, Algül, Hana, Buijs, Jorie, Levy, Philippe, Kiriukova, Mariia, Goni, Elisabetta, Hollenbach, Marcus, Miksch, Rainer C., Kunovsky, Lumir, Vujasinovic, Miroslav, Nikolic, Sara, Dickerson, Luke, Hirth, Michael, Neurath, Markus F., Zumblick, Malte, Vila, Josephine, Jalal, Mustafa, Beyer, Georg, Frost, Fabian, Carrara, Silvia, Kala, Zdenek, Jabandziev, Petr, Sisman, Gurhan, Akyuz, Filiz, Capurso, Gabriele, Falconi, Massimo, Arlt, Alexander, Vleggaar, Frank P., Barresi, Luca, Greenhalf, Bill, Czakó, László, Hegyi, Peter, Hopper, Andrew, Nayar, Manu K., Gress, Thomas M., Vitali, Francesco, Schneider, Alexander, Halloran, Chris M., Trna, Jan, Okhlobystin, Alexey V., Cahen, Djuna L., Bruno, Marco J., Haas, S. L., Overbeek, Kasper A., Poulsen, Jakob L., Lanzillotta, Marco, Vinge-Holmquist, Olof, Macinga, Peter, Demirci, A. Fatih, Sindhunata, Daniko P., Backhus, Johanna, Algül, Hana, Buijs, Jorie, Levy, Philippe, Kiriukova, Mariia, Goni, Elisabetta, Hollenbach, Marcus, Miksch, Rainer C., Kunovsky, Lumir, Vujasinovic, Miroslav, Nikolic, Sara, Dickerson, Luke, Hirth, Michael, Neurath, Markus F., Zumblick, Malte, Vila, Josephine, Jalal, Mustafa, Beyer, Georg, Frost, Fabian, Carrara, Silvia, Kala, Zdenek, Jabandziev, Petr, Sisman, Gurhan, Akyuz, Filiz, Capurso, Gabriele, Falconi, Massimo, Arlt, Alexander, Vleggaar, Frank P., Barresi, Luca, Greenhalf, Bill, Czakó, László, Hegyi, Peter, Hopper, Andrew, Nayar, Manu K., Gress, Thomas M., Vitali, Francesco, Schneider, Alexander, Halloran, Chris M., Trna, Jan, Okhlobystin, Alexey V., Cahen, Djuna L., Bruno, Marco J., and Haas, S. L.

Abstract

Background & Aims: Autoimmune pancreatitis (AIP) is an immune-mediated disease of the pancreas with distinct pathophysiology and manifestations. Our aims were to characterize type 1 AIP in a large pan-European cohort and study the effectiveness of current treatment regimens. Methods: We retrospectively analyzed adults diagnosed since 2005 with type 1 or not-otherwise-specified AIP in 42 European university hospitals. Type 1 AIP was uniformly diagnosed using specific diagnostic criteria. Patients with type 2 AIP and those who had undergone pancreatic surgery were excluded. The primary end point was complete remission, defined as the absence of clinical symptoms and resolution of the index radiologic pancreatic abnormalities attributed to AIP. Results: We included 735 individuals with AIP (69% male; median age, 57 years; 85% White). Steroid treatment was started in 634 patients, of whom 9 (1%) were lost to follow-up. The remaining 625 had a 79% (496/625) complete, 18% (111/625) partial, and 97% (607/625) cumulative remission rate, whereas 3% (18/625) did not achieve remission. No treatment was given in 95 patients, who had a 61% complete (58/95), 19% partial (18/95), and 80% cumulative (76/95) spontaneous remission rate. Higher (≥0.4 mg/kg/day) corticosteroid doses were no more effective than lower (<0.4 mg/kg/day) doses (odds ratio, 0.428; 95% confidence interval, 0.054–3.387) and neither was a starting dose duration >2 weeks (odds ratio, 0.908; 95% confidence interval, 0.818–1.009). Elevated IgG4 levels were independently associated with a decreased chance of complete remission (odds ratio, 0.639; 95% confidence interval, 0.427–0.955). Relapse occurred in 30% of patients. Relapses within 6 months of remission induction were independent of the steroid-tapering duration, induction treatment duration, and total cumulative dose. Conclusions: Patients with type 1 AIP and elevated IgG4 level may need closer monitoring. For remission induction, a starting dose

Published
2024

11. Validation of MRI-morphologic radiological diagnostic criteria in a retrospective cohort of autoimmune pancreatitis (AIP) patients

Author

Goni, Elisabetta, primary, Dikhtyar, Y., additional, Armbruster, M., additional, Ümütlü, M., additional, Vornhülz, M., additional, Sirtl, S., additional, Vielhauer, J., additional, Orgler, E., additional, Klauss, S., additional, Paratore, M., additional, Mahajan, M., additional, Mayerle, J., additional, Beyer, G., additional, and Seidensticker, M., additional

Published
2023
Full Text
View/download PDF

12. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma

Author

Mahajan, Ujjwal Mukund, Langhoff, Eno, Goni, Elisabetta, Costello, Eithne, Greenhalf, William, Halloran, Christopher, Ormanns, Steffen, Kruger, Stephan, Boeck, Stefan, Ribback, Silvia, Beyer, Georg, Dombroswki, Frank, Weiss, Frank-Ulrich, Neoptolemos, John P., Werner, Jens, D’Haese, Jan G., Bazhin, Alexandr, Peterhansl, Julian, Pichlmeier, Svenja, Büchler, Markus W., Kleeff, Jörg, Ganeh, Paula, Sendler, Matthias, Palmer, Daniel H., Kohlmann, Thomas, Rad, Roland, Regel, Ivonne, Lerch, Markus M., and Mayerle, Julia

Published
2018
Full Text
View/download PDF

13. Digital single-operator pancreatoscopy for the treatment of symptomatic pancreatic duct stones: a prospective multicenter cohort trial

Author

Gerges, Christian, Albers, David, Schmitz, Lukas, Goni, Elisabetta, Cappello, Annalisa; https://orcid.org/0000-0002-9248-9549, Schirra, Jörg, Casper, Markus, Dormann, Arno J, Hartmann, Dirk, Hollenbach, Marcus, Schneider, Markus, Denzer, Ulrike W, Dechene, Alexander, Dollhopf, Markus, Mayerle, Julia, Schumacher, Brigitte, van Geenen, Erwin-Jan M, Neuhaus, Horst, Siersema, Peter D, Ellrichmann, Mark, Beyna, Torsten, Gerges, Christian, Albers, David, Schmitz, Lukas, Goni, Elisabetta, Cappello, Annalisa; https://orcid.org/0000-0002-9248-9549, Schirra, Jörg, Casper, Markus, Dormann, Arno J, Hartmann, Dirk, Hollenbach, Marcus, Schneider, Markus, Denzer, Ulrike W, Dechene, Alexander, Dollhopf, Markus, Mayerle, Julia, Schumacher, Brigitte, van Geenen, Erwin-Jan M, Neuhaus, Horst, Siersema, Peter D, Ellrichmann, Mark, and Beyna, Torsten

Abstract

BACKGROUND Digital single-operator pancreatoscopy (DSOP)-guided lithotripsy is a novel treatment modality for pancreatic endotherapy, with demonstrated technical success in retrospective series of between 88 % and 100 %. The aim of this prospective multicenter trial was to systematically evaluate DSOP in patients with chronic pancreatitis and symptomatic pancreatic duct stones. METHODS Patients with symptomatic chronic pancreatitis and three or fewer stones ≥ 5mm in the main pancreatic duct (MPD) of the pancreatic head or body were included. The primary end point was complete stone clearance (CSC) in three or fewer treatment sessions with DSOP. Current guidelines recommend extracorporeal shock wave lithotripsy (ESWL) for MPD stones > 5 mm. A performance goal was developed to show that the CSC rate of MPD stones using DSOP was above what has been previously reported for ESWL. Secondary end points were pain relief measured with the Izbicki pain score (IPS), number of interventions, and serious adverse events (SAEs). RESULTS 40 chronic pancreatitis patients were included. CSC was achieved in 90 % of patients (36/40) on intention-to-treat analysis, after a mean (SD) of 1.36 (0.64) interventions (53 procedures in total). The mean (SD) baseline IPS decreased from 55.3 (46.2) to 10.9 (18.3). Overall pain relief was achieved in 82.4 % (28/34) after 6 months of follow-up, with complete pain relief in 61.8 % (21/34) and partial pain relief in 20.6 % (7/34). SAEs occurred in 12.5 % of patients (5/40), with all treated conservatively. CONCLUSION DSOP-guided endotherapy is effective and safe for the treatment of symptomatic MPD stones in highly selected patients with chronic pancreatitis. It significantly reduces pain and could be considered as an alternative to standard ERCP techniques for MPD stone treatment in these patients.

Published
2023

14. A single-centre prospective, cohort study of the natural history of acute pancreatitis

Author

Cavestro, Giulia Martina, Leandro, Gioacchino, Di Leo, Milena, Zuppardo, Raffaella Alessia, Morrow, Olivia B., Notaristefano, Chiara, Rossi, Gemma, Testoni, Sabrina Gloria Giulia, Mazzoleni, Giorgia, Alessandri, Matteo, Goni, Elisabetta, Singh, Satish K., Giliberti, Aurore, Bianco, Margherita, Fanti, Lorella, Viale, Edi, Arcidiacono, Paolo Giorgio, Mariani, Alberto, Petrone, Maria Chiara, and Testoni, Pier Alberto

Published
2015
Full Text
View/download PDF

16. The influence of gastric atrophy on Helicobacter pylori antibiotics resistance in therapy-naïve patients

Author

Goni, Elisabetta, Tammer, Ina, Schütte, Kerstin, Thon, Cosima, Jechorek, Dörthe, Mahajan, Ujjwal Mukund, Vasapolli, Riccardo, Macke, Lukas, Aulinger, Benedikt, Selgrad, Michael, Link, Alexander, Malfertheiner, Peter, and Schulz, Christian

Subjects
Microbiology (medical), Microbiology
Abstract

BackgroundAntibiotic susceptibility of Helicobacter pylori to antibiotics may vary among different niches of the stomach. The progression of chronic H. pylori gastritis to atrophy changes intragastric physiology that may influence selection of resistant strains.AimTo study the antibiotic resistance of H. pylori taking the severity of atrophic gastritis in antrum and corpus into account.MethodsHelicobacter pylori-positive patients (n = 110, m = 32, mean age 52.6 ± 13.9 years) without prior H. pylori eradication undergoing upper gastrointestinal (GI) endoscopy for dyspeptic symptoms were included in a prospective study. Patients were stratified into three groups depending on the grade of atrophy: no atrophy (OLGA Stage 0), mild atrophy (OLGA Stage I–II) and moderate/severe atrophy (OLGA Stage III–IV). Two biopsies each from the antrum and the corpus and one from the angulus were taken and assessed according to the updated Sydney system. H. pylori strains were isolated from antrum and corpus biopsies and tested for antibiotic susceptibility (AST) for amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and rifampicin by the agar dilution methods. A Chi-square test of independence with a 95% confidence interval was used to detect differences in the proportion of patients with susceptible and resistant H. pylori strains.ResultsAmong 110 patients, primary clarithromycin resistance (R) was 30.0%, both in the antrum and corpus; metronidazole resistance accounted for 36.4 and 34.5% in the antrum and corpus; and levofloxacin was 19.1 and 22.7% in the antrum and corpus, respectively. Resistance rates to amoxicillin, tetracycline, and rifampicin were below 5%. Dual antibiotic resistance rate was 21.8%, and triple resistance rate was 9.1%. There was a significant difference in the resistance rate distribution in antrum (p p ConclusionIn treatment-naïve patients, antibiotic resistance and heteroresistance were related to the severity of atrophy. The high clarithromycin resistance in atrophic gastritis suggests that H. pylori antibiotic susceptibility testing should always be performed in this condition before selecting the eradication regimen.

Published
2022
Full Text
View/download PDF

17. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis

Author

Mahajan, Ujjwal M., primary, Oehrle, Bettina, additional, Sirtl, Simon, additional, Alnatsha, Ahmed, additional, Goni, Elisabetta, additional, Regel, Ivonne, additional, Beyer, Georg, additional, Vornhülz, Marlies, additional, Vielhauer, Jakob, additional, Chromik, Ansgar, additional, Bahra, Markus, additional, Klein, Fritz, additional, Uhl, Waldemar, additional, Fahlbusch, Tim, additional, Distler, Marius, additional, Weitz, Jürgen, additional, Grützmann, Robert, additional, Pilarsky, Christian, additional, Weiss, Frank Ulrich, additional, Adam, M. Gordian, additional, Neoptolemos, John P., additional, Kalthoff, Holger, additional, Rad, Roland, additional, Christiansen, Nicole, additional, Bethan, Bianca, additional, Kamlage, Beate, additional, Lerch, Markus M., additional, and Mayerle, Julia, additional

Published
2022
Full Text
View/download PDF

19. Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board

Author

Heinrich, Kathrin, primary, Miller-Phillips, Lisa, additional, Ziemann, Frank, additional, Hasselmann, Korbinian, additional, Rühlmann, Katharina, additional, Flach, Madeleine, additional, Biro, Dorottya, additional, von Bergwelt-Baildon, Michael, additional, Holch, Julian, additional, Herold, Tobias, additional, von Baumgarten, Louisa, additional, Greif, Philipp A., additional, Jeremias, Irmela, additional, Wuerstlein, Rachel, additional, Casuscelli, Jozefina, additional, Spitzweg, Christine, additional, Seidensticker, Max, additional, Renz, Bernhard, additional, Corradini, Stefanie, additional, Baumeister, Philipp, additional, Goni, Elisabetta, additional, Tufman, Amanda, additional, Jung, Andreas, additional, Kumbrink, Jörg, additional, Kirchner, Thomas, additional, Klauschen, Frederick, additional, Metzeler, Klaus H., additional, Heinemann, Volker, additional, and Westphalen, C. Benedikt, additional

Published
2022
Full Text
View/download PDF

20. SINGLE-OPERATOR VIDEO PANCREATOSCOPY (SOVP) FOR THE MANAGEMENT OF SYMPTOMATIC PANCREATIC DUCT STONES IN SELECTED CHRONIC PANCREATITIS PATIENTS. A PROSPECTIVE MULTICENTRE COHORT TRIAL

Author

Cappello, Annalisa, primary, Schmitz, Lukas, additional, Albers, David, additional, Rousseau, Matthew, additional, Schirra, Jörg, additional, Goni, Elisabetta, additional, Mayerle, Julia, additional, Casper, Markus, additional, Weismüller, Tobias J., additional, Dormann, Arno J., additional, Hartmann, Dirk, additional, Hollenbach, Marcus, additional, Hampe, Jochen, additional, Kandulski, Arne, additional, Hoffman, Arthur, additional, Schlag, Christoph, additional, Denzer, Ulrike, additional, Arlt, Alexander, additional, Dechene, Alexander, additional, Dollhopf, Markus, additional, Schumacher, Brigitte, additional, Van Geenen, Erwin-Jan M., additional, Siersema, Peter D., additional, Neuhaus, Horst, additional, Ellrichmann, Mark, additional, Beyna, Torsten, additional, and Gerges, Christian, additional

Published
2022
Full Text
View/download PDF

22. Increased Number of Colorectal Interval Cancers in Lynch Syndrome after the SARS-CoV-2 Pandemic: A Survey-Based Study.

Author

Russo, Michele, Barchi, Alberto, Mannucci, Alessandro, Puzzono, Marta, Zuppardo, Raffaella Alessia, Biamonte, Paolo, Bencardino, Sarah, Leandro, Gioacchino, Cannizzaro, Renato, Monica, Fabio, Zagari, Rocco Maurizio, Pasquale, Luigi, Goni, Elisabetta, Di Leo, Milena, Ricciardiello, Luigi, and Cavestro, Giulia Martina

Subjects
COVID-19 pandemic, HEREDITARY nonpolyposis colorectal cancer, COLORECTAL cancer, HEREDITARY cancer syndromes, MEDICAL personnel
Abstract

Background: Hereditary colorectal cancer syndromes require timely endoscopic surveillance. Methods: This study evaluated the approach of Italian gastroenterologists to the management of such patients. It then assessed the impact of SARS-CoV-2. All members affiliated with the leading Italian gastroenterology societies (AIGO, SIED, and SIGE) received an online questionnaire. Results: One hundred and twenty-one clinicians from 96 centers answered, not necessarily experts in the field (mean age 50.26 ± 11.22 years). Many collected family history for genetic risk assessment (74.4%), but only 14.0% used an online predictive software. 65.6% discussed cases in multidisciplinary units. Genetic analysis was available to most centers, but only a few hospitals offered dedicated endoscopy (19.0%), outpatient clinics (33.9%), or surgeries (23.1%). Since the start of the SARS-CoV-2 pandemic, the number of clinicians with a high volume of patients decreased (from 38.8% to 28.1%). Almost half of the responders (45.5%) reported a delay in the surveillance (median: 4–12 months). Ultimately, 30.6% detected one interval colorectal cancer in at least one of their patients. Conclusion: The SARS-CoV-2 pandemic directly affected the surveillance of hereditary colorectal cancer syndromes in Italy. Endoscopic surveillance should resume in all centers to avoid the possible long-term consequences of its interruption, especially for inherited colorectal cancer syndromes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.

Author

Dorman, Klara, Zhang, Danmei, Heinrich, Kathrin, Reeh, Laurens, Weiss, Lena, Haas, Michael, Beyer, Georg, Rössler, Daniel, Goni, Elisabetta, Renz, Bernhard W., D'Haese, Jan G., Kunz, Wolfgang G., Seidensticker, Max, Corradini, Stefanie, Niyazi, Maximilian, Ormanns, Steffen, Kumbrink, Jörg, Jung, Andreas, Klauschen, Frederick, and Werner, Jens

Abstract

Background: In pancreatic cancer, systemic treatment options in addition to chemotherapy remain scarce, and so far only a small proportion of patients benefit from targeted therapies. Objective: The patients with pancreatic cancer discussed in the CCCMunichLMU Molecular Tumor Board were reviewed to gain a better real-world understanding of the challenges and chances of precision oncology in this hard-to-treat cancer. Methods: Patients with pancreatic cancer who received comprehensive genomic profiling and were discussed in the interdisciplinary Molecular Tumor Board between May 2017 and July 2022 were included. These patients' medical charts, comprehensive genomic profiling results, and Molecular Tumor Board recommendations were analyzed in this retrospective cohort study. Results: Molecular profiles of 165 patients with pancreatic cancer were discussed in the Molecular Tumor Board. In the 149 cases where comprehensive genomic profiling was successful, KRAS mutations were detected in 87.9%, TP53 in 53.0%, and CDKN2A in 14.1%. 33.3% of KRAS wild-type patients harbored targetable mutations, while these were only found in 19.1% of patients with the KRAS mutation; however, this difference was not statistically significant. 63.8% of patients with successful testing received a targeted treatment recommendation by the Molecular Tumor Board; however, only 3.2% of these were put into practice. Compared to a historic cohort of patients with pancreatic cancer with synchronous metastatic disease diagnosed between 2010 and 2017, the patients from the pancreatic cancer cohort with synchronous metastatic disease had a longer survival. Conclusions: This single-center experience emphasizes the challenges of targeted treatment in pancreatic cancer. Very few patients ultimately received the recommended therapies, highlighting the need for more and better targeted treatment options in pancreatic cancer, early comprehensive genomic profiling to allow sufficient time to put Molecular Tumor Board recommendations into practice, and close cooperation with clinical trial units to give patients access to otherwise not available targeted treatments. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Diet and Lifestyle Habits in Early-Onset Colorectal Cancer: A Pilot Case-Control Study

Author

Puzzono, Marta, primary, Mannucci, Alessandro, additional, Di Leo, Milena, additional, Zuppardo, Raffaella A., additional, Russo, Michele, additional, Ditonno, Ilaria, additional, Goni, Elisabetta, additional, Notaristefano, Chiara, additional, Azzolini, Francesco, additional, Fanti, Lorella, additional, Viale, Edi, additional, Elmore, Ugo, additional, Pantaleo, Giuseppe, additional, Cascinu, Stefano, additional, Rosati, Riccardo, additional, and Cavestro, Giulia Martina, additional

Published
2022
Full Text
View/download PDF

25. Mismatch Repair Deficiency, Chemotherapy and Survival for Resectable Gastric Cancer: an Observational Study from the German staR Cohort and a Meta-Analysis

Author

Stolze, Thilo, primary, Franke, Sabine, additional, Haybaeck, Johannes, additional, Moehler, Markus, additional, Grimminger, Peter P., additional, Lang, Hauke, additional, Roth, Wilfried, additional, Gockel, Ines, additional, Kreuser, Nicole, additional, Bläker, Hendrik, additional, Wittekind, Christian, additional, Lordick, Florian, additional, Vieth, Michael, additional, Veits, Lothar, additional, Waidmann, Oliver, additional, Lingohr, Philipp, additional, Peitz, Ulrich, additional, Schildberg, Claus, additional, Kruschewski, Martin, additional, Vassos, Nikolaos, additional, Goni, Elisabetta, additional, Bruns, Christiane J., additional, Ridwelski, Karsten, additional, Wolff, Stefanie, additional, Lippert, Hans, additional, Schumacher, Johannes, additional, Malfertheiner, Peter, additional, and Venerito, Marino, additional

Published
2021
Full Text
View/download PDF

26. Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric Cancer

Author

Franck, Caspar, primary, Zimmermann, Nadja, primary, Goni, Elisabetta, primary, Lippert, Hans, primary, Ridwelski, Karsten, primary, Kruschewski, Martin, primary, Kreuser, Nicole, primary, Lingohr, Philipp, primary, Schildberg, Claus, primary, Vassos, Nikolaos, primary, Waidmann, Oliver, primary, Peitz, Ulrich, primary, Lang, Hauke, primary, Grmminger, Peter P, primary, Bruns, Christiane, primary, Veits, Lothar, primary, Vieth, Michael, primary, Moehler, Markus, primary, Lordick, Florian, primary, Gockel, Ines, primary, Schumacher, Johannes, primary, Malfertheiner, Peter, primary, and Venerito, Marino, primary

Published
2021
Full Text
View/download PDF

27. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma

Author

Mahajan, Ujjwal Mukund, primary, Alnatsha, Ahmed, additional, Li, Qi, additional, Oehrle, Bettina, additional, Weiss, Frank-Ulrich, additional, Sendler, Matthias, additional, Distler, Marius, additional, Uhl, Waldemar, additional, Fahlbusch, Tim, additional, Goni, Elisabetta, additional, Beyer, Georg, additional, Chromik, Ansgar, additional, Bahra, Markus, additional, Klein, Fritz, additional, Pilarsky, Christian, additional, Grützmann, Robert, additional, Lerch, Markus M., additional, Lauber, Kirsten, additional, Christiansen, Nicole, additional, Kamlage, Beate, additional, Regel, Ivonne, additional, and Mayerle, Julia, additional

Published
2021
Full Text
View/download PDF

28. Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric Cancer

Author

Franck, Caspar, Zimmermann, Nadja, Goni, Elisabetta, Lippert, Hans, Ridwelski, Karsten, Kruschewski, Martin, Kreuser, Nicole, Lingohr, Philipp, Schildberg, Claus, Vassos, Nikolaos, Waidmann, Oliver, Peitz, Ulrich, Lang, Hauke, Grmminger, Peter P., Bruns, Christiane, Veits, Lothar, Vieth, Michael, Moehler, Markus, Lordick, Florian, Gockel, Ines, Schumacher, Johannes, Malfertheiner, Peter, Venerito, Marino, Franck, Caspar, Zimmermann, Nadja, Goni, Elisabetta, Lippert, Hans, Ridwelski, Karsten, Kruschewski, Martin, Kreuser, Nicole, Lingohr, Philipp, Schildberg, Claus, Vassos, Nikolaos, Waidmann, Oliver, Peitz, Ulrich, Lang, Hauke, Grmminger, Peter P., Bruns, Christiane, Veits, Lothar, Vieth, Michael, Moehler, Markus, Lordick, Florian, Gockel, Ines, Schumacher, Johannes, Malfertheiner, Peter, and Venerito, Marino

Abstract

Background & Aims: Symptoms of patients with gastric cancer (GC) are often unspecific and differences in symptoms between patients with cardia and non-cardia GC have been poorly investigated. We aimed to characterize symptoms of patients with cardia and non-cardia GC. Methods: Patients with cardia (Siewert type II and III) and non-cardia GC were recruited in the German multicenter cohort of the Gastric Cancer Research (staR) study between 2013 and 2017. Alarm, dyspeptic and reflux symptoms at the time of presentation were documented using a self-administered questionnaire. Results: A completed self-administered questionnaire was available for 568/759 recruited patients (132 cardia GC, 436 non-cardia GC, male 61%, mean age 64 years). Dyspeptic symptoms were more common in patients with non-cardia GC (69.0 vs. 54.5%, p=0.0024). Cardia GC patients reported more frequently alarm symptoms (69.7 vs. 44.7%, p<0.0001), and were more likely to have Union for International Cancer Control (UICC) stage III-IV (54.1vs. 38.9%, p=0.0034). Especially, dysphagia and weight loss were more common in patients with cardia GC (49.2 vs. 6.4 %, p<0.0001 and 37.1 vs. 25.7%, p=0.02, respectively). No differences between the two groups were observed with respect to reflux symptoms. Patients with alarm symptoms were more likely to have UICC stage III-IV at presentation (69.4 vs. 42.9%, p<0.0001). Conclusions: In clinical practice the symptom pattern at presentation may serve as a hint for tumor localization. Despite the fact that they are common in the general population, dyspeptic symptoms offer a chance for earlier GC detection. Thus, in patients with dyspeptic symptoms who fail empiric approaches, endoscopy should not be delayed.

Published
2021

30. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer

Author

Mahajan, Ujjwal M., Goni, Elisabetta, Langhoff, Enno, Li, Qi, Costello, Eithne, Greenhalf, William, Kruger, Stephan, Ormanns, Steffen, Halloran, Christopher, Ganeh, Paula, Marron, Manuela, Laemmerhirt, Felix, Zhao, Yue, Beyer, Georg, Weiss, Frank-Ulrich, Sendler, Matthias, Bruns, Christiane J., Kohlmann, Thomas, Kirchner, Thomas, Werner, Jens, D'Haese, Jan G., von Bergwelt, Michael, Heinemann, Volker, Neoptolemos, John P., Buechler, Markus W., Belka, Claus, Boeck, Stefan, Lerch, Markus M., Mayerle, Julia, Mahajan, Ujjwal M., Goni, Elisabetta, Langhoff, Enno, Li, Qi, Costello, Eithne, Greenhalf, William, Kruger, Stephan, Ormanns, Steffen, Halloran, Christopher, Ganeh, Paula, Marron, Manuela, Laemmerhirt, Felix, Zhao, Yue, Beyer, Georg, Weiss, Frank-Ulrich, Sendler, Matthias, Bruns, Christiane J., Kohlmann, Thomas, Kirchner, Thomas, Werner, Jens, D'Haese, Jan G., von Bergwelt, Michael, Heinemann, Volker, Neoptolemos, John P., Buechler, Markus W., Belka, Claus, Boeck, Stefan, Lerch, Markus M., and Mayerle, Julia

Abstract

Background: Cathepsin-D (CatD), owing to its dual role as a proteolytic enzyme and as a ligand, has been implicated in cancer progression. The role of CatD in pancreatic ductal adenocarcinoma is unknown. Methods: CatD expression quantified by immunohistochemistry of tumor-tissue microarrays of 403 resected pancreatic cancer patients from the ESPAC-Tplus trial, a translational study within the ESPAC (European Study Group for Pancreatic Cancer) trials, was dichotomously distributed to low and high H scores (cut off 22.35) for survival and multivariable analysis. The validation cohort (n = 69) was recruited based on the hazard ratio of CatD from ESPAC-Tplus. 5-fluorouracil-, and gemcitabine-resistant pancreatic cancer cell lines were employed for mechanistic experiments. All statistical tests were two-sided. Results: Median overall survival was 23.75 months and median overall survival for patients with high CatD expression was 21.09 (95% confidence interval [CI] = 17.31 to 24.80) months vs 27.20 (95% CI = 23.75 to 31.90) months for low CatD expression (chi(2)(LR), (1DF) = 4.00; P = .04). Multivariable analysis revealed CatD expression as a predictive marker in gemcitabine-treated (z stat = 2.33; P = .02) but not in 5-fluorouracil-treated (z stat = 0.21; P = .82) patients. An independent validation cohort confirmed CatD as a negative predictive marker for survival (chi(2)(LR), (1DF)= 6.80; P = .009) and as an independent predictive marker in gemcitabine-treated patients with a hazard ratio of 3.38 (95% CI = 1.36 to 8.38, P = .008). Overexpression of CatD was associated with a concomitant suppression of the acid sphingomyelinase, and silencing of CatD resulted in upregulation of acid sphingomyelinase with rescue of gemcitabine resistance. Conclusions: Adjuvant gemcitabine is less effective in pancreatic ductal adenocarcinoma with high CatD expression, and thus CatD could serve as a marker for biomarker-driven therapy.

Published
2020

31. Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research

Author

Weise, Friederike, Vieth, Michael, Reinhold, Dirk, Haybaeck, Johannes, Goni, Elisabetta, Lippert, Hans, Ridwelski, Karsten, Lingohr, Philipp, Schildberg, Claus, Vassos, Nikolaos, Kruschewski, Martin, Krasniuk, Iurii, Grimminger, Peter P., Waidmann, Oliver, Peitz, Ulrich, Veits, Lothar, Kreuser, Nicole, Lang, Hauke, Bruns, Christiane, Moehler, Markus, Lordick, Florian, Gockel, Ines, Schumacher, Johannes, Malfertheiner, Peter, Venerito, Marino, Weise, Friederike, Vieth, Michael, Reinhold, Dirk, Haybaeck, Johannes, Goni, Elisabetta, Lippert, Hans, Ridwelski, Karsten, Lingohr, Philipp, Schildberg, Claus, Vassos, Nikolaos, Kruschewski, Martin, Krasniuk, Iurii, Grimminger, Peter P., Waidmann, Oliver, Peitz, Ulrich, Veits, Lothar, Kreuser, Nicole, Lang, Hauke, Bruns, Christiane, Moehler, Markus, Lordick, Florian, Gockel, Ines, Schumacher, Johannes, Malfertheiner, Peter, and Venerito, Marino

Abstract

Objectives Patients with autoimmune gastritis (AIG) are reported to have an increased risk of developing gastric cancer (GC). In this study, we assess the characteristics and outcomes of GC patients with AIG in a multicenter case-control study. Methods Between April 2013 and May 2017, patients with GC, including cancers of the esophagogastric junction (EGJ) Siewert type II and III, were recruited. Patients with histological characteristics of AIG were identified and matched in a 1:2 fashion for age and gender to GC patients with no AIG. Presenting symptoms were documented using a self-administered questionnaire. Results Histological assessment of gastric mucosa was available for 572/759 GC patients. Overall, 28 (4.9%) of GC patients had AIG (67 +/- 9 years, female-to-male ratio 1.3:1). In patients with AIG, GC was more likely to be localized in the proximal (i.e. EGJ, fundus, corpus) stomach (odds ratio (OR) 2.7, 95% confidence interval (CI) 1.0-7.1). In GC patients with AIG, pernicious anemia was the leading clinical sign (OR 22.0, 95% CI 2.6-187.2), and the most common indication for esophagogastroduodenoscopy (OR 29.0, 95% CI 7.2-116.4). GC patients with AIG were more likely to present without distant metastases (OR 6.2, 95% CI 1.3-28.8) and to be treated with curative intention (OR 3.0, 95% CI 1.0-9.0). The five-year survival rates with 95% CI in GC patients with and with no AIG were 84.7% (83.8-85.6) and 53.5% (50.9-56.1), respectively (OR 0.25, 95% CI 0.08-0.75, p = 0.001). Conclusions Pernicious anemia leads to earlier diagnosis of GC in AIG patients and contributes significantly to a better clinical outcome.

Published
2020

32. Gastric cancer in autoimmune gastritis: A case‐control study from the German centers of the staR project on gastric cancer research

Author

Weise, Friederike, primary, Vieth, Michael, additional, Reinhold, Dirk, additional, Haybaeck, Johannes, additional, Goni, Elisabetta, additional, Lippert, Hans, additional, Ridwelski, Karsten, additional, Lingohr, Philipp, additional, Schildberg, Claus, additional, Vassos, Nikolaos, additional, Kruschewski, Martin, additional, Krasniuk, Iurii, additional, Grimminger, Peter P, additional, Waidmann, Oliver, additional, Peitz, Ulrich, additional, Veits, Lothar, additional, Kreuser, Nicole, additional, Lang, Hauke, additional, Bruns, Christiane, additional, Moehler, Markus, additional, Lordick, Florian, additional, Gockel, Ines, additional, Schumacher, Johannes, additional, Malfertheiner, Peter, additional, and Venerito, Marino, additional

Published
2020
Full Text
View/download PDF

33. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer

Author

Mahajan, Ujjwal M, primary, Goni, Elisabetta, primary, Langhoff, Enno, primary, Li, Qi, primary, Costello, Eithne, primary, Greenhalf, William, primary, Kruger, Stephan, primary, Ormanns, Steffen, primary, Halloran, Christopher, primary, Ganeh, Paula, primary, Marron, Manuela, primary, Lämmerhirt, Felix, primary, Zhao, Yue, primary, Beyer, Georg, primary, Weiss, Frank-Ulrich, primary, Sendler, Matthias, primary, Bruns, Christiane J, primary, Kohlmann, Thomas, primary, Kirchner, Thomas, primary, Werner, Jens, primary, D’Haese, Jan G, primary, von Bergwelt-Baildon, Michael, primary, Heinemann, Volker, primary, Neoptolemos, John P, primary, Büchler, Markus W, primary, Belka, Claus, primary, Boeck, Stefan, primary, Lerch, Markus M, primary, and Mayerle, Julia, primary

Published
2019
Full Text
View/download PDF

34. Cathepsin D expression mediates gemcitabine resistance in pancreatic cancer

Author

Mahajan, Ujjwal Mukund, primary, Goni, Elisabetta, additional, Langhoff, Enno, additional, Li, Qi, additional, Costello, Eithne, additional, Greenhalf, William, additional, Kruger, Stephan, additional, Ormanns, Steffen, additional, Halloran, Christopher, additional, Ganeh, Paula, additional, Marron, Manuela, additional, Lämmerhirt, Felix, additional, Zhao, Yue, additional, Beyer, Georg, additional, Weiss, Frank Ulrich, additional, Sendler, Matthias, additional, Bruns, Christine J., additional, Kohlmann, Thomas, additional, Kirchner, Thomas, additional, Werner, Jens, additional, D'Haese, Jan, additional, von Bergwelt-Baildon, Michael, additional, Heinemann, Volker, additional, Neoptolemos, John P., additional, Büchler, Markus W., additional, Belka, Claus, additional, Boeck, Stefan, additional, Lerch, Markus M., additional, and Mayerle, Julia, additional

Published
2019
Full Text
View/download PDF

35. Immunogenetic profile and IgG4 levels discriminate among autoimmune pancreatitis type 1 and 2: A multicentric prospective study in the Caucasian population

Author

Goni, Elisabetta, primary, Beyer, Georg, additional, Amodio, Antonio, additional, Mahajan, Ujjwal Mukund, additional, Regel, Ivonne, additional, Ricco', Matteo, additional, De Marchi, Giulia, additional, Bonatti, Francesco, additional, Martorana, Davide, additional, Neri, Tauro Maria, additional, Cavestro, Giulia Martina, additional, Frulloni, Luca, additional, and Mayerle, Julia, additional

Published
2019
Full Text
View/download PDF

36. Chronic Pancreatitis Prognosis Score (COPPS): preliminary results from a prospective multicenter, international validation study

Author

Garbe, Annamaria, primary, Mahajan, Ujjwal M., additional, Kohlmann, Thomas, additional, Goni, Elisabetta, additional, Budde, Christoph, additional, Martinez-Moneo, Emma, additional, Shimosegawa, Tooru, additional, Forsmark, Chris, additional, Garg, Pramod, additional, Gomes, António P., additional, Stigliano, Serrena, additional, Conwell, Darwin, additional, Lerch, Markus M., additional, Mayerle, Julia, additional, and Beyer, Georg, additional

Published
2019
Full Text
View/download PDF

38. Predictive Value of the 'DICA' Endoscopic Classification on the Outcome of Diverticular Disease of the Colon: An International Study

Author

Tursi, Antonio, Brandimarte, Giovanni, Mario, Francesco Di, Annunziata, Maria L., Bafutto, Mauro, Bianco, Maria A., Cassieri, Claudio, Conigliaro, Rita, Danese, Silvio, Bastiani, Rudi De, Desserud, Kari F., Cesare, Luigi Di, Elisei, Walter, Escalante, Ricardo, Faggiani, Roberto, Fiorella, Serafina, Forti, Giacomo, Goni, Elisabetta, Graziani, Maria G., Lai, Maria A., Latella, Giovanni, Lecca, Piera Giuseppina, Oliveira, Enio C., Papa, Alfredo, Penna, Antonio, Pigò, Flavia, Portincasa, Piero, Rotondano, Gianluca, Søreide, Kjetil, Spadaccini, Antonio, Usai, Paolo, Bonovas, Stefanos, Scarpignato, Carmelo, Zampaletta, Costantino, and Picchio, Marcello .

Published
2016

39. Non-invasive assessment of gastric secretory function in centenarians

Author

Tursi, Antonio, primary, De Bastiani, Rudi, additional, Franceschi, Marilisa, additional, Goni, Elisabetta, additional, Riccò, Matteo, additional, Venerito, Marino, additional, Rugge, Massimo, additional, Scarpignato, Carmelo, additional, Picchio, Marcello, additional, Di Mario, Francesco, additional, and Collaborative group, The Primary Care, additional

Published
2017
Full Text
View/download PDF

41. Gastric Cancer in Autoimmune Gastritis: A Case–Control Study from the Star Project on Gastric Cancer Research

Author

Venerito, Marino, primary, Weise, Friederike, additional, Goni, Elisabetta, additional, Reinhold, Dirk, additional, Ridwelski, Karsten, additional, Lingohr, Philipp, additional, Matthaei, Hanno, additional, Schildberg, Claus, additional, Kruschewski, Martin, additional, Krasniuk, Iurii, additional, Grimminger, Peter P., additional, Moehler, Markus, additional, Wolff, Stefanie, additional, Lippert, Hans, additional, Vieth, Michael, additional, Veits, Lothar, additional, Bruns, Christiane, additional, Lordick, Florian, additional, Gockel, Ines, additional, Malfertheiner, Peter, additional, and Schumacher, Johannes, additional

Published
2017
Full Text
View/download PDF

42. Helicobacter pylori and extragastric diseases

Author

Goni, Elisabetta, Franceschi, Francesco, Franceschi, Francesco (ORCID:0000-0001-6266-445X), Goni, Elisabetta, Franceschi, Francesco, and Franceschi, Francesco (ORCID:0000-0001-6266-445X)

Abstract

During the past year, many articles were published on the extragastric diseases related to Helicobacter pylori infection. This supports the theory that some microorganisms may cause diseases even far from the primary site of infection by interfering with different biologic processes. The role of H. pylori on idiopathic thrombocytopenic purpura, sideropenica anemia, and vitamin B12 deficiency is well known. On the other hand, there is a growing interest in the bacterium's association with cardiovascular, neurologic, hematologic, dermatologic, head and neck, and uro-gynecologic diseases, as well as diabetes mellitus and metabolic syndrome, with very promising results. This review has been aimed at summarizing the results of the most relevant studies published over the last year on this fascinating topic.

Published
2016

47. Sa1408 Predictive Value of the “DICA” Endoscopic Classification on the Outcome of Diverticular Disease of the Colon: An International Study

Author

Tursi, Antonio, primary, Brandimarte, Giovanni, additional, Di Mario, Francesco, additional, Annunziata, Maria L., additional, Bafutto, Mauro, additional, Bianco, Maria A., additional, Cassieri, Claudio, additional, Conigliaro, Rita, additional, Danese, Silvio, additional, De Bastiani, Rudi, additional, Desserud, Kari F., additional, Di Cesare, Luigi, additional, Elisei, Walter, additional, Escalante, Ricardo, additional, Faggiani, Roberto, additional, Fiorella, Serafina, additional, Forti, Giacomo, additional, Goni, Elisabetta, additional, Graziani, Maria G., additional, Lai, Maria A., additional, Latella, Giovanni, additional, Lecca, Piera Giuseppina, additional, Oliveira, Enio C., additional, Papa, Alfredo, additional, Penna, Antonio, additional, Pigò, Flavia, additional, Portincasa, Piero, additional, Rotondano, Gianluca, additional, Søreide, Kjetil, additional, Spadaccini, Antonio, additional, Usai, Paolo, additional, Bonovas, Stefanos, additional, Scarpignato, Carmelo, additional, Zampaletta, Costantino, additional, and Picchio, Marcello, additional

Published
2016
Full Text
View/download PDF

49. Clinical and Radiological Follow-up of Subjects with Chronic Asymptomatic Pancreatic Hyperenzymemia

Author

Granato, Anna, Amodio, Antonio, De Pretis, Nicolò, De Marchi, Giuilia, Tumelero, Tiziana, Goni, Elisabetta, Gabbrielli, Armando, Vantini, Italo, Benini, Luigi, and Frulloni, Luca

Subjects
Meeting Abstracts, Pancreas
Abstract

Context Chronic asymptomatic pancreatic hyperenzymemia (CAPH) has been described since 1996 as a benign disease. Pathological findings at magnetic resonance cholangiopancreatography (MRCP) with secretin stimulation (s-MRCP) have been found in 50% of CAPH subjects, but in 30% their clinical meaning remains undefined. Objective To investigate subjects with CAPH during the follow-up to assess the clinical and radiological outcome. Methods From January 2012 to March 2013, a cohort of 160 subjects previously studied for CAPH were re-evaluate with s-MRCP and biochemical tests. Results Clinical data relative to 108 subjects were collected, whereas 68 (47 males, 21 females; mean age: 49.8 ± 12.2 years) underwent s-MRCP. Clinically, acute pancreatitis was observed in one subject out of 108 (0.9%) after 5 years from the first detection of hyperenzymemia. Among the 68 subjects who underwent s-MRCP, 23 (33.8%) had previous s-RMCP normal and 45 (66.2%) pathological. No radiological alterations in 23 subjects with normal s-MRCP at first evaluation were observed at follow-up, whereas unchanged s-MRCP was documented in 41 out of 45 (91.1%) subjects with pathological s-MRCP at first evaluation after mean follow-up of 3±2 years. One out of 11 subject with IPMN had progression of the size of the cyst, 1 out of 11 with suspected sphincter of Oddi dysfunction showed an increase of Wirsung duct diameter, while a worsening of ductal morphology was observed in 2 out of 20 subjects with suspected chronic pancreatitis. Conclusion CAPH subjects remain asymptomatic during the follow-up. Subjects with previous normal MRCP-s did not show pathological findings at follow-up whereas only a small percentage of those with previous suspected sphincter of Oddi dysfunction or chronic pancreatitis, showed a progression at imaging in a short term follow-up., JOP. Journal of the Pancreas, Vol 14, N° 5S (2013): September (Suppl.) - p. 528-602

Published
2013
Full Text
View/download PDF

50. Extracorporeal Membrane Oxygenation in Predominantly Leuco- and Thrombocytopenic Haematologic/Oncologic Patients with Acute Respiratory Distress Syndrome - a Single-Centre Experience.

Author

Stecher, Stephanie-Susanne, Beyer, Georg, Goni, Elisabetta, Tischer, Johanna, Herold, Tobias, Schulz, Christoph, op den Winkel, Mark, Stemmler, H. Joachim, and Lippl, Stephanie

Subjects
EXTRACORPOREAL membrane oxygenation, ADULT respiratory distress syndrome, CRITICAL care medicine, PATIENT acceptance of health care, CANCER chemotherapy
Abstract

Aims: The acute respiratory distress syndrome (ARDS) is a frequent condition following pneumonia in immunocompromised cancer patients. Extracorporeal membrane oxygenation (ECMO) may serve as a rescue therapy in refractory ARDS but has still not been studied in predominantly leuco- and thrombocytopenic cancer patients. Patients and Methods: In this monocentric, retrospective, observational study, we assessed all cancer patients treated with ECMO for ARDS between 2013 and 2017. Results: 25 patients, 11 of whom underwent haematopoietic stem cell transplantation (SCT), were analysed. The main reason for ARDS was pneumonia in 72%. All patients were under invasive ventilation at ECMO. All but 9/3 patients suffered from leuco-/thrombocytopenia due to anti-cancer treatment or underlying disease. Overall, 17 patients (68%) died on ECMO, whereas 5 patients survived to hospital discharge (20%). All patients after recent allogeneic (allo-)SCT have died. 4 patients experienced severe bleeding events. Conclusions: Discouraging survival rates in patients treated after allo-SCT do not support the use of ECMO for ARDS in this patient subgroup. On the contrary, cancer patients in at least stable disease otherwise eligible for full-code intensive care unit management, even those with severe thrombocytopenia, may be potential candidates for ECMO in case of severe ARDS failing conventional measures. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results